



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 83329

Title: Exit strategies in Inflammatory Bowel Disease: looking beyond anti-TNFs

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05083795

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor, Doctor, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: Italy

Manuscript submission date: 2023-01-20

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2023-02-11 04:41

Reviewer performed review: 2023-02-12 15:10

Review time: 1 Day and 10 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors reviewed the recent advances in the exit strategies in IBD, and made many comments or viewpoints in the field. The review could give the readers valuable information in this critically important question. There are some concerns listed as follows. 1. As for the title “in the era of small molecules”, it is not quite accurate or proper. In this review, the data about small molecules is very limited. 2. As the revolution of the treatment targets are changing, the timing of decalation or stop of certain medications are definitely changing. There are many evidences about anti-TNF agents. It is important to mention the timing or indication of exit stratageis, based on clinical remission or endoscopic healing. It is the key point for the clinical practice. 3. In this review, the authors did not discuss the exit of 5ASA in UC. If the authors did not aim to review it, should mention it in the manuscript. 4. In Conclusion section, it will be very helpful to give some prospectives in the field.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 83329

Title: Exit strategies in Inflammatory Bowel Disease: looking beyond anti-TNFs

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 01467363

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Full Professor

Reviewer's Country/Territory: Slovenia

Author's Country/Territory: Italy

Manuscript submission date: 2023-01-20

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2023-02-13 13:25

Reviewer performed review: 2023-02-19 08:45

Review time: 5 Days and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Title: accurately reflects the topic and contents of the paper. Abstract: is appropriate, not structured, 151 words. Key words: 6 key words, precisely define the content of the paper. Core tip: is appropriate, 46 words. Introduction: 268 words, the reader is briefly acquainted with known facts about IBD treatment with immunosuppressive treatment, novel biologics, such as anti- $\alpha 4\beta 7$ integrin and anti- IL12/23 antibodies, and small molecules. The content of the article is divided into 5 additional chapters: individual chapters present: selecting the ideal candidate for therapy withdrawal, discuss exit strategies with the patient, withdrawal, de-escalation and re-treatment, optimal monitoring after therapy withdrawal. Certain drugs (immunomodulator monotherapy, anti-TNF monotherapy, combination therapy of immunomodulator and anti-TNF, anti- $\alpha 4\beta 7$ integrin antibody: vedolizumab, anti-IL12/23 antibody: ustekinumab, JAK inhibitors: tofacitinib) and research results are presented and discussed in individual subsections. The discussion in individual subsections is appropriate, supported by relevant references. Conclusion: 289 words, authors conclude with known (in the past already often written) thought "Further prospective studies are needed to improve

decision making and guidelines". The conclusion is by no means original. References: 95, influential journals in this field N Engl J Med, Dig Dis Sci, Aliment Pharmacol Ther, J Crohns Colitis, Inflamm Bowel Dis, Am J Gastroenterol,... Conflict of interest: there are no financial conflicts of interest to disclose. Opinion of the reviewer The article provides a carefully written overview of an increasingly important field. In it, I miss the reflection about the role of pharmacogenomic research, which affects the selection of treatment options for individual patients. "Personalized medicine" is likely to influence treatment discontinuation decisions in patients with IBD.